Hibiskus aspires to emerge as the leading company in selective proteasome inhibition by targeting each of the 7 human proteasome catalytic ß subunits with its macrolactam drug candidates. While proteasome suppression is a well-established mechanism for FDA-approved medications, its potential applications in diseases have been relatively limited, predominantly in multiple myeloma, a condition affecting the production of antibodies by blood cells. Since the proteasome is present in all eukaryotic cells, small molecules that specifically target a single proteasome among many (and a sub-catalytic activity) hold potential for numerous pharmaceutical purposes.